Home › NCT05380349

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

RecruitingEarly phase 1

A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Histological diagnosis of GBM (WHO grade 4)
* Subjects ≥18 years of age
* Patients must have a life expectancy of \>6 months
* Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)
* Patients must have a KPS rating of ≥70
* Patients should not have received any prior systemic anti-cancer therapy
* Patients must be negative for HIV, Hepatitis B and C
* Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:

  * Hemoglobin (Hgb)\> 8 g/dL
  * Absolute Neutrophil Count (ANC) \> 1,000/mm3
  * Platelet count \> 100,000/mm3
  * Creatinine \< 2 mg/dL
  * Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \< 3x upper limit of normal (ULN)

Exclusion Criteria:

* Metastatic disease
* Diseases or conditions that obscure toxicity or dangerously alter drug metabolism
* Serious intercurrent medical illness
* Inadequately controlled hypertension
* History of myocardial infarction or unstable angina within 6 months
* History of stroke or transient ischemic attack within 6 months

About the study

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

What is being tested

combinations of up to 3 FDA approved drugs from a panel of compounds (drug)

Sponsor: Swedish Medical Center · Participants: 10 · Started: Apr 19, 2024

Contact the study team

Charles S Cobbs, M.D. · Phone: 206-320-2300
Parvinder Hothi, Ph.D. · Phone: 206-320-3145

Official record on ClinicalTrials.gov — NCT05380349

Locations in the U.S.

Washington

Swedish Medical Center, Seattle

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.